Xeris Biopharma Holdings, Inc.XERS
| Dec 31, 2021 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 |
---|
Cash and cash equivalents | 67 | 122 | 51 | 46 |
---|
Short-term Investments | 35 | - | 44 | 34 |
---|
Trade accounts receivable, net | 17 | 31 | 31 | 30 |
---|
Inventory | 18 | 25 | 29 | 37 |
---|
Prepaid Expense, Current | 5 | 9 | 11 | 8 |
---|
Total current assets | 143 | 187 | 166 | 156 |
---|
Property and equipment, net | 7 | 6 | 6 | 7 |
---|
Operating lease right-of-use assets | - | 4 | 4 | 24 |
---|
Goodwill | 23 | 23 | 23 | 23 |
---|
Intangible Assets, Net (Excluding Goodwill) | 131 | 121 | 118 | 115 |
---|
Other assets | 1 | 5 | 5 | 5 |
---|
Total assets | 304 | 345 | 321 | 329 |
---|
Accounts payable | 9 | 5 | 12 | 12 |
---|
Current operating lease liabilities | - | 2 | 1 | 2 |
---|
Other accrued liabilities | 49 | 37 | 20 | 19 |
---|
AccrualForRebatesAndTradeDiscounts | 15 | 17 | 17 | 17 |
---|
Accrued returns reserve | 4 | 11 | 13 | 11 |
---|
Other current liabilities | 2 | 3 | 3 | 2 |
---|
Total current liabilities | 79 | 74 | 81 | 80 |
---|
Long-term Debt | 88 | 187 | 188 | 188 |
---|
Operating Lease, Liability, Noncurrent | - | 9 | 9 | 35 |
---|
Contingent value rights | 23 | 26 | 9 | 7 |
---|
Supply Agreements, Liability, Noncurrent | 6 | - | - | - |
---|
Deferred rent | 7 | - | - | - |
---|
Deferred tax liabilities | 5 | 4 | 4 | 3 |
---|
Other liabilities | 2 | 0 | 0 | 3 |
---|
Total liabilities | 209 | 299 | 291 | 315 |
---|
Common Stock, Value, Issued | 0 | 0 | 0 | 0 |
---|
Additional paid in capital | 555 | 600 | 602 | 605 |
---|
Accumulated deficit | -460 | -555 | -572 | -591 |
---|
Accumulated other comprehensive income (loss) | -0 | -0 | -0 | -0 |
---|
Total stockholders' equity | 95 | 45 | 30 | 14 |
---|
Total liabilities and stockholders' equity | 304 | 345 | 321 | 329 |
---|